Abstracts

Ten Years of Strengthening Laboratory Services and Systems: Then, Now, and the Future

The last 10 years have been transformational for laboratory medicine in Africa thanks to increase in global health funding, especially from the world bank, PEPFAR, the Global fund–etc. Laboratory networks have been established, systems developed, and human competent work force developed –etc. In fact a recent Institute of Medicine (IOM) report has described laboratory health…

Pathogenesis of Acute HCV Infection

Hepatitis C virus (HCV) infects 170 million people worldwide; most persons who are acutely infected will develop chronic infection, while 25% of people will spontaneously clear the virus. Because of common routes of transmission, HIV-1/HCV co-infection is highly prevalent. In HIV-1/HCV co-infection, the likelihood of spontaneous clearance is worsened. While we do not fully understand…

HCV Treatment as Prevention: Challenges and Opportunities

Major recent advances in hepatitis C virus (HCV) therapeutic development, with highly curative well tolerated all oral regimens now available have raised the prospect that treatment could provide considerable prevention impact. Mathematical modelling has demonstrated that rapid scale-up of interferon-free direct acting antiviral (DAA) therapy among people who inject drugs (PWID) to levels of 4-8%…

HCV Therapeutics: It’s the Virus, Stupid

In 1986, Hoofnagle and coworkers reported the initial use of recombinant interferon alfa to treat patients with non-A, non-B hepatitis, demonstrating improvement in serum ALT levels in most patients. Over the ensuing decade, hepatitis C virus was identified cause of non-A, non-B hepatitis and molecular techniques were applied to test HCV RNA response during therapy,…

HCV Therapeutics: Big Sticks With Big Stickers

The new all oral direct acting antiviral agents (DAA) for HCV have permanently changed the treatment landscape for patients with Hepatitis C (HCV). Because of better tolerability, fewer side effects and shorter length of therapy, the majority of HCV patients are now eligible for treatment and most patients who know they have HCV are eager…

Varenicline vs Placebo for Smoking Cessation: ANRS 144 Inter-ACTIV Randomized Trial

Background: About half of HIV-infected patients are regular tobacco smokers in Europe, a higher prevalence than the general population. Tobacco is an important determinant of non AIDS morbidity and mortality (including vascular diseases and malignancies), a major reason to promote tobacco cessation. It is unclear whether varenicline is safe and efficacious for smoking cessation in…

Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors

Background: Although lipoatrophy is uncommon with current antiretroviral therapy (ART), fat accumulation continues to occur, and its association with protease inhibitors (PIs) has been questioned. The effect of integrase inhibitors vs. PIs on body composition has not been established. Methods: We compared the percentage change in lean mass (by DXA), peripheral fat (limb fat by…